Scopus BioPharma Inc (SCPS)
0.0011
0.00 (0.00%)
USD |
OTCM |
May 17, 14:00
Scopus BioPharma Cash from Operations (TTM): -3.043M for June 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2023 | -3.043M |
| March 31, 2023 | -4.909M |
| December 31, 2022 | -8.127M |
| September 30, 2022 | -11.85M |
| June 30, 2022 | -13.52M |
| March 31, 2022 | -12.61M |
| December 31, 2021 | -11.42M |
| September 30, 2021 | -8.195M |
| June 30, 2021 | -6.340M |
| Date | Value |
|---|---|
| March 31, 2021 | -5.195M |
| December 31, 2020 | -2.525M |
| September 30, 2020 | -2.212M |
| June 30, 2020 | -2.152M |
| March 31, 2020 | -1.959M |
| December 31, 2019 | -2.120M |
| September 30, 2019 | -1.626M |
| June 30, 2019 | -1.236M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-13.52M
Minimum
Jun 2022
-1.236M
Maximum
Jun 2019
-5.826M
Average
-4.909M
Median
Mar 2023
Cash from Operations (TTM) Benchmarks
| NovaBay Pharmaceuticals Inc | -4.516M |
| Palatin Technologies Inc | -33.74M |
| iBio Inc | -18.89M |
| Theriva Biologics Inc | -18.27M |
| Oragenics Inc | -7.291M |